Treatment of Patients With Anxiety Disorder (0777-022)

Phase 2

Completed

• Conditions: Generalized Anxiety Disorder

• Registration Number: NCT00539578
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2002-09
• Primary Completion: 2003-02
• Study Completion: 2003-02
• Study First Submitted: 2007-10-01
• Study First Submitted QC: 2007-10-03
• Study First Posted: 2007-10-04
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-30
• Last Update Posted: 2015-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

• Male and Female patients ages 18 to 70

Read More

Exclusion Criteria

• Women who are breastfeeding or pregnant
• Positive result at prestudy on urine drug screen for illicit drugs
• History of alcohol or drug abuse

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL